• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS.

作者信息

Seyger M M B, Reich A, El Baou C, Schuster C, Riedl E, Paller A S

机构信息

Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.

Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland.

出版信息

J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e911-e913. doi: 10.1111/jdv.17564. Epub 2021 Aug 27.

DOI:10.1111/jdv.17564
PMID:34320259
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9291077/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b8/9291077/6227d696ff28/JDV-35-e911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b8/9291077/6227d696ff28/JDV-35-e911-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91b8/9291077/6227d696ff28/JDV-35-e911-g001.jpg

相似文献

1
Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS.司库奇尤单抗治疗中重度银屑病患儿甲银屑病的疗效：来自IXORA-PEDS的事后分析
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e911-e913. doi: 10.1111/jdv.17564. Epub 2021 Aug 27.
2
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).在一项针对中度至重度斑块状银屑病儿科患者的III期随机双盲安慰剂对照研究（IXORA-PEDS）中，司库奇尤单抗的疗效和安全性。
Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15.
3
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis.指甲银屑病不会影响中重度银屑病患者对依奇珠单抗的皮肤反应。
J Drugs Dermatol. 2020 Aug 1;19(8):741-746. doi: 10.36849/JDD.2020.5116.
4
Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.在有显著指甲受累的中度至重度斑块状银屑病患者中，司库奇尤单抗疗效显著：UNCOVER 3研究结果
J Drugs Dermatol. 2016 Aug 1;15(8):958-61.
5
Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).IXORA-PEDS 研究：依奇珠单抗治疗中重度斑块状银屑病儿童患者的群体药代动力学和暴露-疗效分析。
Br J Clin Pharmacol. 2022 Mar;88(3):1074-1086. doi: 10.1111/bcp.15034. Epub 2021 Sep 2.
6
Ixekizumab in nail psoriasis.司库奇尤单抗治疗甲银屑病
Dermatol Ther. 2020 May;33(3):e13352. doi: 10.1111/dth.13352. Epub 2020 Apr 9.
7
Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3.依奇珠单抗治疗 5 年实现指甲银屑病持续缓解：来自 UNCOVER-3 的事后分析。
Acta Derm Venereol. 2022 Oct 10;102:adv00787. doi: 10.2340/actadv.v102.2269.
8
Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.依奇珠单抗治疗中重度斑块状银屑病的儿科患者。
Expert Opin Biol Ther. 2021 Aug;21(8):983-990. doi: 10.1080/14712598.2021.1931679. Epub 2021 Jun 9.
9
Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.优特克单抗IV期临床试验中指甲银屑病治疗的指甲银屑病严重程度指数改善率标准的确定：MARCOPOLO研究
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):e298-e299. doi: 10.1111/jdv.14083. Epub 2017 Jan 3.
10
Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis.小分子抑制剂和生物制剂治疗甲银屑病：系统评价和网络荟萃分析。
J Am Acad Dermatol. 2021 Jul;85(1):135-143. doi: 10.1016/j.jaad.2021.01.024. Epub 2021 Jan 19.

引用本文的文献

1
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.从治疗中度至重度银屑病和银屑病关节炎的临床试验看司库奇尤单抗治疗甲银屑病的疗效综述
Rheumatol Ther. 2023 Oct;10(5):1127-1146. doi: 10.1007/s40744-023-00553-1. Epub 2023 Jul 3.
2
Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3.依奇珠单抗治疗 5 年实现指甲银屑病持续缓解：来自 UNCOVER-3 的事后分析。
Acta Derm Venereol. 2022 Oct 10;102:adv00787. doi: 10.2340/actadv.v102.2269.

本文引用的文献

1
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis.网络荟萃分析比较生物制剂治疗实现指甲银屑病完全缓解的疗效。
J Dermatolog Treat. 2022 May;33(3):1652-1660. doi: 10.1080/09546634.2021.1892024. Epub 2021 Mar 1.
2
Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis.小分子抑制剂和生物制剂治疗甲银屑病：系统评价和网络荟萃分析。
J Am Acad Dermatol. 2021 Jul;85(1):135-143. doi: 10.1016/j.jaad.2021.01.024. Epub 2021 Jan 19.
3
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
中度至重度斑块状银屑病患者中，依奇珠单抗与古塞库单抗的头对头比较：一项随机双盲试验的24周疗效和安全性结果。
Br J Dermatol. 2021 Jun;184(6):1047-1058. doi: 10.1111/bjd.19509. Epub 2020 Oct 25.
4
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S).中度至重度银屑病患者中，司库奇尤单抗与优特克单抗治疗甲银屑病的疗效：一项3期头对头研究（IXORA-S）的52周结果
Dermatol Ther (Heidelb). 2020 Aug;10(4):663-670. doi: 10.1007/s13555-020-00383-x. Epub 2020 May 15.
5
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).在一项针对中度至重度斑块状银屑病儿科患者的III期随机双盲安慰剂对照研究（IXORA-PEDS）中，司库奇尤单抗的疗效和安全性。
Br J Dermatol. 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15.
6
Nail Involvement as a Predictor of Disease Severity in Paediatric Psoriasis: Follow-up Data from the Dutch ChildCAPTURE Registry.指甲受累可预测儿童银屑病的疾病严重程度：荷兰儿童 CAP 注册研究的随访数据。
Acta Derm Venereol. 2019 Feb 1;99(2):152-157. doi: 10.2340/00015555-3036.
7
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.司库奇尤单抗治疗可改善中度至重度银屑病患者的指甲银屑病：UNCOVER-3随机、对照和开放标签阶段的结果
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2.
8
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.在中度至重度银屑病中比较依奇珠单抗与依那西普或安慰剂的疗效（UNCOVER-2 和 UNCOVER-3）：两项 3 期随机临床试验的结果。
Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.
9
Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States.儿童银屑病的临床表现：美国一项多中心研究的结果
Pediatr Dermatol. 2013 Jul-Aug;30(4):424-8. doi: 10.1111/pde.12072. Epub 2013 Jan 30.
10
Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals.儿童银屑病的流行病学和处方治疗：医学专业人员调查。
J Dermatolog Treat. 2009;20(5):254-8. doi: 10.1080/09546630902911847.